Table 5.
Effect of silencing various pathways on cytotoxicity of classical anti-cancer drugs in MCF-7 cells. Data is presented as mean ± SD compared to CA/drug.
| Treatment on MCF-7 Cells | Drug Concentration | ||
|---|---|---|---|
| 10 pM | 100 pM | 1 nM | |
| CA/Pac/AKT | 10.93 ± 1.05 | 8.33 ± 0.84 | 3.31 ± 0.45 |
| CA/Pac/ERBB2 | 7.25 ± 1.91 | 4.11 ± 0.35 | 3.40 ± 1.81 |
| CA/Pac/MAPK | −10.79 ± 2.12 | 1.53 ± 0.55 | 2.06 ± 0.35 |
| CA/Pac/ROS1 | 4.19 ± 1.41 | 3.14 ± 0.74 | 3.64 ± 0.19 |
| CA/Doc/AKT | 5.14 ± 1.22 | 10.45 ± 1.33 | 11.69 ± 2.18 |
| CA/Doc/ERBB2 | 8.95 ± 2.28 | 10.25 ± 0.99 | 14.28 ± 1.04 |
| CA/Doc/MAPK | 3.22 ± 0.91 | 4.27 ± 0.08 | 3.67 ± 1.72 |
| CA/Doc/ROS1 | 1.06 ± 0.59 | 2.83 ± 0.71 | 1.25 ± 0.53 |